NICE IDs

06/11/2020

ID1400: Upadacitinib for treating severe rheumatoid arthritis

30/10/2020

ID740: Liraglutide for managing overweight and obesity

23/10/2020

ID1443: Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer

14/10/2020

ID3732: Bulevirtide for treating chronic hepatitis D

12/10/2020

ID885: Short bowel syndrome - teduglutide

12/10/2020

ID1572: Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484)

12/10/2020

ID1559: Nivolumab for previously treated squamous non-small-cell lung cancer (CDF Review TA483)

12/10/2020

ID1577: Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416)

12/10/2020

ID3786: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (rapid review TA621)

10/09/2020

ID1532: Ixekizumab for treating axial spondyloarthritis after NSAIDs

09/09/2020

ID1599: Nintedanib for treating progressive fibrosing interstitial lung disease

07/09/2020

ID1592: Ranibizumab for treating diabetic retinopathy

07/09/2020

ID901: Non-bisphosphonates for treating osteoporosis

07/09/2020

ID1672: Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease

07/09/2020

ID1185: Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura

07/09/2020

ID3808: Remdesivir for treating COVID-19

04/09/2020

ID1549: Givosiran for treating acute hepatic porphyria

28/08/2020

ID1412: Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer

28/08/2020

ID1477: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

21/08/2020

ID1326: Volanesorsen for treating familial chylomicronaemia syndrome